{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:09:14Z","timestamp":1792238954108,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370729"],"award-info":[{"award-number":["82370729"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203670"],"award-info":[{"award-number":["82203670"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The role of hypoxia-inducible factor 2\u03b1 (HIF2\u03b1) in clear cell Renal Cell Carcinoma (ccRCC) is still not fully understood. In this study, we identified that urinary prolegumain levels positively correlated with the malignant characteristics of ccRCC. In cultured 786-O and OSRC-2 cells, HIF2\u03b1 downregulation reduced prolegumain secretion. RNA sequencing assay revealed that HIF2\u03b1 induces methylation-controlled J (MCJ), a negative regulator on the mitochondrial respiratory chain. Silencing MCJ reduced prolegumain secretion, and MCJ overexpression restored prolegumain secretion inhibited by HIF2\u03b1 downregulation. Chromatin immunoprecipitation and luciferase assay confirmed MCJ as a transcription target of HIF2\u03b1. Furthermore, we showed the ectopic MCJ overexpression reversed the improved mitochondrial damage resulting from HIF2\u03b1 downregulation, as evidenced by electron microscope, ATP level, GSSG\/GSH ratio, MitoSOX, and DHE staining. Through mass spectrometry analysis, we identified oxidation site His343 on the legumain sequence as contributing to the prolegumain secretion. Therapeutically, silencing MCJ or HIF2\u03b1 or using ROS scavengers Vitamin C or MitoQ alleviated MMP2 activation as well as cell migration and tube formation. In a mouse orthotopic xenograft model of ccRCC, silencing MCJ or administration of MitoQ significantly protected against mitochondrial damage and subsequently reduced the lung metastasis of tumors. Overall, our study identified MCJ as a target molecule of HIF2\u03b1 in ccRCC. Silencing MCJ or using ROS scavengers like MitoQ can suppress oxidation site His343 in legumain, preventing prolegumain secretion and subsequently reducing metastasis of ccRCC.<\/jats:p>","DOI":"10.1038\/s41419-025-07432-3","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T12:48:21Z","timestamp":1739450901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HIF2\u03b1 drives ccRCC metastasis through transcriptional activation of methylation-controlled J protein and enhanced prolegumain secretion"],"prefix":"10.1038","volume":"16","author":[{"given":"Tianyu","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dekun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxiang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-488X","authenticated-orcid":false,"given":"Shijing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhujun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-9063","authenticated-orcid":false,"given":"Xiaoyue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"7432_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","volume":"82","author":"L Bukavina","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of Renal Cell Carcinoma: 2022 Update. Eur Urol. 2022;82:529\u201342.","journal-title":"Eur Urol"},{"key":"7432_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clinicians. 2023;73:17\u201348.","journal-title":"CA Cancer J Clinicians"},{"key":"7432_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8:865\u201373.","journal-title":"Nat Rev Cancer"},{"key":"7432_CR4","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/sj.ki.5000221","volume":"69","author":"VH Haase","year":"2006","unstructured":"Haase VH. The VHL\/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int. 2006;69:1302\u20137.","journal-title":"Kidney Int"},{"key":"7432_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","volume":"23","author":"C Shen","year":"2013","unstructured":"Shen C, Kaelin WG Jr. The VHL\/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23:18\u201325.","journal-title":"Semin Cancer Biol"},{"key":"7432_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","volume":"26","author":"TK Choueiri","year":"2020","unstructured":"Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26:1519\u201330.","journal-title":"Nat Med"},{"key":"7432_CR7","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1:E83.","journal-title":"PLoS Biol"},{"key":"7432_CR8","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25:5675\u201386.","journal-title":"Mol Cell Biol"},{"key":"7432_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature19795","volume":"539","author":"H Cho","year":"2016","unstructured":"Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, et al. On-target efficacy of a HIF-2\u03b1 antagonist in preclinical kidney cancer models. Nature. 2016;539:107\u201311.","journal-title":"Nature"},{"key":"7432_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0014-5793(98)01574-9","volume":"441","author":"JM Chen","year":"1998","unstructured":"Chen JM, Rawlings ND, Stevens RAE, Barrett AJ. Identification of the active site of legumain links it to caspases, clostripain and gingipains in a new clan of cysteine endopeptidases. FEBS Lett. 1998;441:361\u20135.","journal-title":"FEBS Lett"},{"key":"7432_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.biochi.2015.09.022","volume":"122","author":"E Dall","year":"2016","unstructured":"Dall E, Brandstetter H. Structure and function of legumain in health and disease. Biochimie. 2016;122:126\u201350.","journal-title":"Biochimie"},{"key":"7432_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1042\/bj3350111","volume":"335","author":"JM Chen","year":"1998","unstructured":"Chen JM, Dando PM, Stevens RA, Fortunato M, Barrett AJ. Cloning and expression of mouse legumain, a lysosomal endopeptidase. Biochemical J. 1998;335:111\u20137.","journal-title":"Biochemical J"},{"key":"7432_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrm2745","volume":"10","author":"P Saftig","year":"2009","unstructured":"Saftig P, Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol cell Biol. 2009;10:623\u201335.","journal-title":"Nat Rev Mol cell Biol"},{"key":"7432_CR14","first-page":"2957","volume":"63","author":"C Liu","year":"2003","unstructured":"Liu C, Sun C, Huang H, Janda K, Edgington T. Overexpression of legumain in tumors is significant for invasion\/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 2003;63:2957\u201364.","journal-title":"Cancer Res"},{"key":"7432_CR15","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/jcb.24143","volume":"113","author":"L Wang","year":"2012","unstructured":"Wang L, Chen S, Zhang M, Li N, Chen Y, Su W, et al. Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem. 2012;113:2679\u201386.","journal-title":"J Cell Biochem"},{"key":"7432_CR16","doi-asserted-by":"publisher","first-page":"e52980","DOI":"10.1371\/journal.pone.0052980","volume":"8","author":"MH Haugen","year":"2013","unstructured":"Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, et al. Nuclear legumain activity in colorectal cancer. PloS one. 2013;8:e52980.","journal-title":"PloS one"},{"key":"7432_CR17","doi-asserted-by":"crossref","unstructured":"Zhang W, Lin Y. The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review. Cells. 2021;10:1153.","DOI":"10.3390\/cells10051153"},{"key":"7432_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41589-022-00992-x","volume":"18","author":"Y Kovalyova","year":"2022","unstructured":"Kovalyova Y, Bak DW, Gordon EM, Fung C, Shuman JHB, Cover TL. et al. An infection-induced oxidation site regulates legumain processing and tumor growth. Nat Chem Biol. 2022;18:698\u2013705.","journal-title":"Nat Chem Biol"},{"key":"7432_CR19","doi-asserted-by":"crossref","unstructured":"Wang QQ, Lu CM, Li K, Xia YM, Qiu L, Lin JG. Legumain-mediated self-assembly of a 131I-labelled agent for targeted radiotherapy of tumors. J Mater Chem B. 2022;10:2251\u20139.","DOI":"10.1039\/D1TB02862F"},{"key":"7432_CR20","doi-asserted-by":"crossref","unstructured":"Shen L, Shi YZ, Xun J, Chen CA, Du LF, Tan XY, et al. Legumain-contained exosomes mediate remodeling of tumor extracellular matrix and protumor effects of TAMs. Cancer Res. 2016;76:5086.","DOI":"10.1158\/1538-7445.AM2016-5086"},{"key":"7432_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/cr.2014.4","volume":"24","author":"LX Zhao","year":"2014","unstructured":"Zhao LX, Hua T, Crowley C, Ru H, Ni XM, Shaw N, et al. Structural analysis of asparaginyl endopeptidase reveals the activation mechanism and a reversible intermediate maturation stage. Cell Res. 2014;24:344\u201358.","journal-title":"Cell Res"},{"key":"7432_CR22","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52:D174\u2013D82.","journal-title":"Nucleic Acids Res"},{"key":"7432_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09277-9","volume":"10","author":"Y Zou","year":"2019","unstructured":"Zou Y, Palte MJ, Deik AA, Li HX, Eaton JK, Wang WY, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10:1617.","journal-title":"Nat Commun"},{"key":"7432_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01970-x","volume":"8","author":"L Barbier-Torres","year":"2017","unstructured":"Barbier-Torres L, Iruzubieta P, Fernandez-Ramos D, Delgado TC, Taibo D, Guitierrez-de-Juan V, et al. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nat Commun. 2017;8:2068.","journal-title":"Nat Commun"},{"key":"7432_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100276","volume":"3","author":"P Iruzubieta","year":"2021","unstructured":"Iruzubieta P, Goikoetxea-Usandizaga N, Barbier-Torres L, Serrano-Macia M, Fernandez-Ramos D, Fernandez-Tussy P, et al. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. JHEP Rep. 2021;3:100276.","journal-title":"JHEP Rep"},{"key":"7432_CR26","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.7150\/thno.41001","volume":"10","author":"L Fabbri","year":"2020","unstructured":"Fabbri L, Dufies M, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, et al. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-\u0394C in clear cell Renal Cell Carcinoma patients. Theranostics. 2020;10:2696\u2013713.","journal-title":"Theranostics"},{"key":"7432_CR27","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.2174\/1381612826666201125111625","volume":"27","author":"BD Reddy","year":"2021","unstructured":"Reddy BD, Beeraka NM, Chitturi CMK, Madhunapantula SV. An Overview of Targeting Legumain for Inhibiting Cancers. Curr Pharm Des. 2021;27:3337\u201348.","journal-title":"Curr Pharm Des"},{"key":"7432_CR28","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.15252\/embj.201796750","volume":"36","author":"R Vidmar","year":"2017","unstructured":"Vidmar R, Vizovisek M, Turk D, Turk B, Fonovic M. Protease cleavage site fingerprinting by label-free in-gel degradomics reveals pH-dependent specificity switch of legumain. EMBO J. 2017;36:2455\u201365.","journal-title":"EMBO J"},{"key":"7432_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biochi.2017.05.009","volume":"139","author":"NN Lunde","year":"2017","unstructured":"Lunde NN, Haugen MH, Bodin Larsen KB, Damgaard I, Pettersen SJ, Kasem R, et al. Glycosylation is important for legumain localization and processing to active forms but not for cystatin E\/M inhibitory functions. Biochimie. 2017;139:27\u201337.","journal-title":"Biochimie"},{"key":"7432_CR30","doi-asserted-by":"publisher","first-page":"dju012","DOI":"10.1093\/jnci\/dju012","volume":"106","author":"Y Lin","year":"2014","unstructured":"Lin Y, Qiu Y, Xu C, Liu Q, Peng B, Kaufmann GF, et al. Functional role of asparaginyl endopeptidase ubiquitination by TRAF6 in tumor invasion and metastasis. J Natl Cancer Inst. 2014;106:dju012.","journal-title":"J Natl Cancer Inst"},{"key":"7432_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.febslet.2007.02.064","volume":"581","author":"Y Morita","year":"2007","unstructured":"Morita Y, Araki H, Sugimoto T, Takeuchi K, Yamane T, Maeda T, et al. Legumain\/asparaginyl endopeptidase controls extracellular matrix remodeling through the degradation of fibronectin in mouse renal proximal tubular cells. FEBS Lett. 2007;581:1417\u201324.","journal-title":"FEBS Lett"},{"key":"7432_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/jnci\/djz156","volume":"112","author":"JJ Manfredi","year":"2020","unstructured":"Manfredi JJ. Inactivation of Wild-Type p53 by Asparagine Endopeptidase in Glioblastoma: An Opportunity to Target the \u201cUndruggable. J Natl Cancer Inst. 2020;112:327\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"7432_CR33","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1128\/MCB.00189-13","volume":"33","author":"KM Hatle","year":"2013","unstructured":"Hatle KM, Gummadidala P, Navasa N, Bernardo E, Dodge J, Silverstrim B, et al. MCJ\/DnaJC15, an Endogenous Mitochondrial Repressor of the Respiratory Chain That Controls Metabolic Alterations. Mol Cell Biol. 2013;33:2302\u201314.","journal-title":"Mol Cell Biol"},{"key":"7432_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16991-2","volume":"11","author":"L Barbier-Torres","year":"2020","unstructured":"Barbier-Torres L, Fortner KA, Iruzubieta P, Delgado TC, Giddings E, Chen Y, et al. Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation. Nat Commun. 2020;11:3360.","journal-title":"Nat Commun"},{"key":"7432_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer cell. 2002;1:237\u201346.","journal-title":"Cancer cell"},{"key":"7432_CR36","doi-asserted-by":"publisher","first-page":"13023","DOI":"10.1073\/pnas.2002567117","volume":"117","author":"K Hong","year":"2020","unstructured":"Hong K, Hu L, Liu X, Simon JM, Ptacek TS, Zheng X, et al. USP37 promotes deubiquitination of HIF2\u03b1 in kidney cancer. Proc Natl Acad Sci USA. 2020;117:13023\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7432_CR37","first-page":"447","volume":"12","author":"H Yang","year":"2001","unstructured":"Yang H, Kaelin WG Jr. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ. 2001;12:447\u201355.","journal-title":"Cell Growth Differ"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07432-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07432-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T12:48:25Z","timestamp":1739450905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07432-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7432"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07432-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Animal Experimentation Ethics Committee of Nankai University, Tianjin, China. (Approval No. 2023-SYDWLL-000613). All of the experiments were performed in accordance with the Basel Declaration. The research on human samples was conducted with the approval of the Ethics Committee of Nankai University, Tianjin, China. (Approval No. NKUIRB2023147). All participants provided written informed consent, and the study was carried out in compliance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"93"}}